Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00894439 | Study Evaluating BLI-489 and Piperacillin in Healthy Subjects | PHASE1 | COMPLETED | 24 | — | — | May 1, 2009 | Jul 1, 2009 | Jul 17, 2009 | 1 | United States |
| NCT00820404 | Study Evaluating Single Doses of BLI-489 in Healthy Subjects | PHASE1 | COMPLETED | 54 | — | — | Jan 1, 2009 | Apr 1, 2009 | Jul 17, 2009 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| BLI-489/Piperacillin | DRUG | - |
| BLI-489 | DRUG | - |
| Piperacillin | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Men or women of non-childbearing potential, aged 18 to 50 years of age inclusive at screening. 2. Body mass index (BMI) in the range of 18 to 32 kg/m2 and body weight greater than or equal to 50 kg. 3. Healthy as determined by the investigator on the basis of the screening ev...